Common side effects of<unk>  include hot flashes (25–28% vs. 18–21% for placebo), vaginal dryness, and leg cramps (generally mild; 5.5% vs. 1.9% for placebo).<unk>  does not cause breast tenderness, endometrial hyperplasia, menstrual bleeding, or endometrial cancer. It does not appear to affect cognition or memory.<unk>  is a teratogen; i.e., it can cause developmental abnormalities such as birth defects.<unk>  may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, and vision changes. Black box warnings were added to the label of<unk>  in 2007 warning of increased risk of death due to stroke for postmenopausal women with documented coronary heart disease or at increased risk for major coronary events, as well as increased risk for deep vein thrombosis and pulmonary embolism. The risk of venous thromboembolism with<unk>  is increased by several-fold in postmenopausal women ( = 3.1).<unk>  has a lower risk of thromboembolism than tamoxifen. In the MORE trial,<unk>  caused a 40% decrease in risk of cardiovascular events in women who were at increased risk for coronary artery disease, although there was no decrease in cardiovascular events for the group as a whole. A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen and<unk>  used to treat breast cancer, significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects. A recent human case report in July 2016 suggests that<unk>  may in fact, at some point, also stimulate breast cancer growth leading to a reduction of advanced breast cancer disease upon the withdrawal of the drug. Unlike other SERMs, such as tamoxifen,<unk>  has no risk of uterine hyperplasia or endometrial cancer ( = 0.8).<unk>  does not increase the incidence of breast pain or tenderness in postmenopausal women.
Raloxifene
Bazedoxifene
Lasofoxifene
Ormeloxifene
Tamoxifen
Denosumab
Endoxifen
Teriparatide